Skip to main content

Mavenclad FDA Approval History

Last updated by Judith Stewart, BPharm on Nov 6, 2019.

FDA Approved: Yes (First approved March 29, 2019)
Brand name: Mavenclad
Generic name: cladribine
Dosage form: Tablets
Company: EMD Serono, Inc.
Treatment for: Multiple Sclerosis

Mavenclad (cladribine) is a purine antimetabolite indicated for the treatment of relapsing forms of multiple sclerosis (MS).

Development timeline for Mavenclad

DateArticle
Mar 29, 2019Approval FDA Approves Mavenclad (cladribine) Tablets for Multiple Sclerosis
Jul 30, 2018FDA Accepts File for Cladribine Tablets as Potential Treatment for Relapsing Forms of Multiple Sclerosis
Jun 22, 2011Merck: Regulatory Update on Cladribine Tablets
Mar  2, 2011Merck Receives Complete Response Letter From FDA on Cladribine Tablets New Drug Application
Nov 29, 2010Merck KGaA Announces Extension of FDA Priority Review Period for Cladribine Tablets for the Treatment of Relapsing Forms of MS
Jul 28, 2010FDA Grants Priority Review to Cladribine Tablets for the Treatment of Relapsing Forms of Multiple Sclerosis
Jun  8, 2010Merck Resubmits U.S. Application for Cladribine Tablets as a Potential MS Therapy
Nov 30, 2009Merck KGaA Receives Refuse to File Letter from FDA on Cladribine Tablets New Drug Application
Oct  2, 2009Merck Submits Application for Cladribine Tablets as a Potential Oral Short-Course Multiple Sclerosis Therapy in the United States

See also

Mavenclad (cladribine) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer